Freshfields and Clifford Chance Advise on UCB’s $680 Million Sale

In Short: Belgian biopharma giant UCB is selling its portfolio of established products in China, including epilepsy drug Keppra and antihistamine Zyrtec, to Singapore's CBC Group and Abu Dhabi’s Mubadala Investment Co. for $680 million. This move allows UCB to focus on developing new medicines in China, especially in areas like immunology and neurology.